The North America Bioconjugation Market is witnessing significant growth due to rising biopharmaceutical investments, an increasing prevalence of chronic diseases, and advancements in drug delivery technologies. The market size was valued at USD 1,050 million in 2025 and is expected to reach USD 2,780 million by 2035, growing at a CAGR of 9.2% from 2024 to 2035.
The economic impact of tariffs on "North America Bioconjugation Market".
Market Growth Drivers
Rising Investments in Biopharmaceutical Research: Companies like Thermo Fisher Scientific and Merck are increasing investments in the development of next-generation bioconjugates for targeted therapies. With increased funding in R&D and collaborations with academic institutions, these firms enhance market innovation, resulting in improved therapeutics and diagnostics. Additionally, public-private partnerships have accelerated pipelines for antibody-drug conjugate development, contributing to market expansion.
Growing Adoption in Diagnostic Imaging: Bioconjugation technologies are increasingly deployed to develop highly sensitive imaging agents, particularly for cancer diagnostics. For instance, PerkinElmer has expanded its bioconjugation reagent portfolio for use in preclinical and clinical imaging systems. This improves diagnostic accuracy and personalized medicine approaches, propelling the adoption of novel bioconjugates across hospitals and research centers in North America.
Market Trends
Expansion of Site-Specific Conjugation Technologies: Companies such as Seagen and Catalent are focusing on advancing site-specific conjugation technologies to enhance the efficacy and safety of antibody-drug conjugates (ADCs). These innovations are aimed at improving bioavailability, reducing off-target effects, and increasing payload delivery efficiency, reflecting a move toward highly targeted biotherapeutics in oncology and rare diseases.
Emergence of Bioconjugation for RNA Therapeutics: The adoption of bioconjugation in RNA drug delivery is gaining momentum, with players like Moderna exploring conjugate-based delivery vehicles for mRNA therapeutics. This trend is driving the development of more stable, effective, and tissue-specific therapies in the burgeoning RNA medicines market, further catalyzing growth across North America.
Market Opportunity
Rising Demand for ADC-based Cancer Therapies: With increasing cancer incidence and a robust pipeline of antibody-drug conjugates, companies like Pfizer and ImmunoGen have opportunities to commercialize novel ADC products addressing unmet oncological needs.
Expansion in Personalized Medicine: The growing emphasis on precision medicine is creating opportunities for market players to develop custom bioconjugates for targeted therapies, particularly in autoimmune disorders, cardiovascular disease, and infectious disease management.
North America Bioconjugation Market Revenue (USD Million), 2020-2035
The revenue trend for the North America Bioconjugation Market shows a steady and substantial rise from 2020 through 2035. Beginning at USD 540 million in 2020, the market experiences accelerated growth after 2023, reaching USD 1,050 million in 2025 and projected to more than double to USD 2,780 million by 2035. This upsurge is driven primarily by increased biopharma R&D activities, strategic alliances, and new product launches in personalized medicine and targeted therapies. The consistent year-over-year upward momentum reflects expanding applications in diagnostics, therapeutics, and drug delivery.
North America Bioconjugation Market by Regions Share (%), 2025
In 2025, the United States dominates the North America Bioconjugation Market, holding a 72% market share, reflecting its leading role in biopharmaceutical R&D, clinical trials, and commercial adoption. Canada follows with 17%, supported by robust government funding and a growing biotech sector. Mexico captures 6% of market share, driven by expanding clinical research activities. Other North American regions, including Puerto Rico and Bermuda, together account for 5%, indicating incremental contributions but limited market influence. This regional disparity is shaped by differences in healthcare infrastructure, innovation investments, and regulatory environments.
Recent Developments in North America Bioconjugation Market
In February 2024, Thermo Fisher Scientific launched a new suite of click chemistry bioconjugation kits designed for rapid and site-specific antibody labeling. This release enables researchers to achieve higher conjugation efficiency and reproducibility in ADC development, expanding options for both large-scale manufacturing and laboratory-scale experiments.
In April 2024, Seagen and Pfizer completed a strategic collaboration agreement to co-develop next-generation antibody-drug conjugates targeting difficult-to-treat solid tumors. This partnership aims to accelerate early-phase clinical trials and commercialize novel bioconjugates in the U.S. and Canadian markets.
In May 2024, Catalent announced the expansion of its Madison, Wisconsin facility to increase production capacity for bioconjugated therapies. This facility upgrade will scale up GMP manufacturing to meet growing demand for biologic and conjugate-based drug products, supporting North American and global clients in accelerating time-to-market for new drugs.
Press Releases